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Abstract
Ataxin-1 (Atx1), a member of the polyglutamine (polyQ) expanded protein family, is responsible for spinocerebellar ataxia
type 1. Requirements for developing the disease are polyQ expansion, nuclear localization and phosphorylation of S776.
Using a combination of bioinformatics, cell and structural biology approaches, we have identified a UHM ligand motif (ULM),
present in proteins associated with splicing, in the C-terminus of Atx1 and shown that Atx1 interacts with and influences the
function of the splicing factor U2AF65 via this motif. ULM comprises S776 of Atx1 and overlaps with a nuclear localization
signal and a 14-3-3 binding motif. We demonstrate that phosphorylation of S776 provides the molecular switch which
discriminates between 14-3-3 and components of the spliceosome. We also show that an S776D Atx1 mutant previously
designed to mimic phosphorylation is unsuitable for this aim because of the different chemical properties of the two
groups. Our results indicate that Atx1 is part of a complex network of interactions with splicing factors and suggest that
development of the pathology is the consequence of a competition of aggregation with native interactions. Studies of the
interactions formed by non-expanded Atx1 thus provide valuable hints for understanding both the function of the non-
pathologic protein and the causes of the disease.
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Introduction
Ataxin-1 (Atx1) is a 98 kDa protein and a member of the
protein family containing polymorphic polyglutamine (polyQ)
tracts related to neurodegenerative diseases [1–3]. Although
clinically distinct, these pathologies are all caused by a common
mechanism: when the polyQ tract is anomalously expanded above
a threshold which varies for each disease the polyQ carrier protein
misfolds and aggregates leading to cellular death. Expansion in
Atx1 above 35–42 glutamines is associated with spinocerebellar
ataxia type 1 (SCA1), an autosomal dominant neurodegenerative
disorder characterized by motor coordination deficits caused by
progressive loss of Purkinje cells in the cerebellar cortex and
neurons in the brain stem and spinocerebellar tracts.
A causative link between polyQ expansion and the disease
process is now generally accepted. However, the importance of
other regions of the carrier proteins, the so-called ‘‘protein
context’’, has been increasingly appreciated in the past few years
[4–6]. At the same time, the concept that SCA1 pathology
depends on alteration of native protein interactions, rather than on
acquisition of new aberrant interactions mediated by polyQ, has
gained growing consensus. Atx1 regions other than the polyQ tract
have been functionally and structurally characterized and shown
to mediate native protein-protein interactions, and to modulate
the process of aggregation and pathogenesis [7–14]. A major
advance in the process of unraveling the molecular bases of SCA1
pathogenesis was achieved by showing that expansion of the
polyQ tract is necessary but not sufficient to cause pathology:
expanded Atx1 does not produce cerebellar degeneration if it lacks
regions other than the polyQ tract such as a nuclear localization
signal (NLS) [15] or the AXH domain [14], or if a serine to
alanine mutation prevents phosphorylation at residue 776 [16].
Phosphorylation by Akt kinase of this residue, located at a site
remote from the polyQ tract, is also essential for Atx1 binding to
the multifunctional regulatory protein 14-3-3 [17]. It was also
shown that polyQ expansion of Atx1 differentially affects the
function of the protein in the context of endogenous protein
complexes. In the context of nuclear interactions for instance, it
favours the formation of a protein complex containing SPF45, also
known as RBM17 [18], a factor which regulates alternative
splicing through interactions with other splicing factors [19–21],
thus contributing to SCA1 neuropathology via a gain-of-function
mechanism. Concomitantly, polyQ expansion attenuates the
formation and function of another protein complex containing
Atx1/Capicua, contributing to SCA1 via a partial loss-of-function
mechanism. These results lead directly to the question of which
function of Atx1 is modulated by 14-3-3 and by the other factors
and how this is linked to pathology.
With the aim of addressing these questions, we set out to study
in more detail the mechanism(s) which determine the Atx1
interactome. We found that Atx1 contains a UHM ligand motif
(ULM), previously identified in splicing factors [21], which
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region, which comprises S776, mediates Atx1 interaction with the
UHM domains, RRM-like motifs exclusively present in pre-
mRNA processing factors [22,23]. We assessed that two nuclear
proteins, the constitutive element of the spliceosome U2AF65 and
the regulatory factor SPF45, both identified in the pre-spliceosome
complex, also known as complex A [24,25], and previously found
in the Atx1 interactome [18,26], bind the protein in vitro through a
similar ULM/UHM recognition mechanism [21–23]. We show by
co-immunoprecipitation and co-localization experiments using
native as well as over-expressed proteins, that U2AF65 interacts
both with polyQ non-expanded and expanded Atx1. The
interaction appeared to have a positive effect on the splicing
activity of U2AF65. Finally, we investigated how phosphorylation
of S776 modulates interaction and found that, while not
significantly changing the affinity for the two UHM proteins, it
determines a quantitative shift towards complex formation with
14-3-3. This suggests that the interaction with 14-3-3 has the role
of segregating Atx1 in a high affinity complex, thus preventing
interaction with UHM domains. We conclude that rather than by
a ‘simplistic’ gain- or loss-of-function mechanism, SCA1 pathology
is triggered by complex alterations of its normal interactome, some
of which even exert a protective role against disease.
Results
Atx1 Contains a Sequence Match to the UHM Ligand
Motif
In an attempt to shed light on the Atx1 function(s), we analyzed
its sequence with the ELM resource for predicting functional short
linear motifs in eukaryotic proteins [27,28]. ELM revealed a short
pattern (RKRRWS) in the Atx1 region 771–776 (Figure 1A)
which gives a perfect match with the UHM ligand motif (ULM).
This motif, first identified in the constitutive splicing factors SF1
and SAP155 and known to bind to the UHM domain of U2AF65
[21], is C-terminal to the previously identified AXH domain [8,9],
which is essential for several of the Atx1 functions, including a
putative role in transcriptional regulation [10–14]. Alignment of
Atx1 from different species shows that the ULM match is highly
conserved within the Atx1 family but diverges in the Atx1-like
Boat protein (Figure 1B). This suggests that transcriptional
regulation of the AXH domain is uncoupled from the ULM
function. Atx1 ULM is absent in D. melanogaster and C. elegans
where Atx1 is very divergent and spans almost exclusively the
AXH domain, but is present in the mosquito homologue.
As for most linear motifs [28,29], ULMs have so far been found
only in regions of natively unstructured proteins. The region
around this putative motif of Atx1 is predicted as natively
disordered [30] (data not shown). We concluded from sequence
analysis and from the knowledge that Atx1 is also present in the
nucleus where splicing occurs, that the match to ULM is a strong
linear motif candidate and that, if validated experimentally, it
could provide useful insights into the Atx1 function.
The putative Atx1 ULM overlaps with two other motifs. An
already identified ‘‘mode II’’ recognition site for the adaptor
molecule 14-3-3 (RXXpSXP) is located in the region 773–778
[17,31]. Also this motif, like Atx1 ULM, includes S776 that has
been shown to be phosphorylated by Akt kinase in cell and to play a
critical role in SCA1 pathogenesis [16]. In addition, the nuclear
localization signal (NLS) of Atx1 has been located at 771–774
(RKRR), overlapping with both ULM and 14-3-3 ligand motifs, as
the K772T mutant causes a shift in distribution of Q82-expanded
Atx1 to the cytoplasm in transgenic mouse and prevents the
development of the disease [15].
Atx1 Recognizes UHM Domains
To assess whether Atx1 recognizes the U2AF65 UHM domain
through its putative ULM motif, we performed a titration
experiment by NMR and followed the chemical shift perturbation
of
15N U2AF65 UHM HSQC spectrum upon addition of an
unlabelled Atx1 ULM peptide (residues 769–777). The chemical
shift variations observed at low ionic strength (30 mM NaCl) are
comparable to those observed for SF1 ULM (residues 11–25)
under the same conditions [23] suggesting that SF1 ULM and
Atx1 ULM bind to U2AF65 UHM in a similar way (Figure 2).
No significant changes were observed beyond a peptide:protein
equimolar ratio. Disappearance of the spectrum of the free form
and appearance of peaks arising from the bound form indicate that
Atx1 ULM binds tightly in a slow exchange regime in the NMR
time scale, which is indicative of a Kd in the nanomolar range for
the U2AF65 UHM/Atx1 ULM interaction.
Phosphorylation of Atx1 S776 Reduces but Does Not
Abolish the Interaction with U2AF65 UHM
It has been suggested that, when present in ULM motifs, serine
phosphorylation regulates association to UHM [23]. In order to
check whether phosphorylation of Atx1 S776 by Akt kinase [17]
prevents the interaction with U2AF65 UHM, in analogy with
what observed for SF1 S20 [32], we performed a titration
experiment by NMR following the chemical shift perturbation of
15N labeled U2AF65 UHM upon addition of unlabelled
phosphorylated Atx1 ULM (Atx1_pS_ULM) using the same
conditions used for the non-phosphorylated peptide. Atx1_
pS_ULM showed to bind U2AF65 UHM without appreciable
Figure 1. Sequence analysis. A. Schematic representation of the
Atx1 architecture. The positions of the polyQ tract (Q) and of the AXH
motif are indicated as well as S776. B. Alignment of the ULM motif in
Atx1 orthologs and of the corresponding Boat sequences. The
alignment was coloured according to standard coding. Sequence
numbering follows human Atx1.
doi:10.1371/journal.pone.0008372.g001
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values and direction of the chemical shift perturbation as
compared to the non-phosphorylated peptide (Figure 2).
To quantify even a small weakening of the binding caused by
phosphorylation of S776 we measured the dissociation constants
(Kd) by Iso-Thermal Calorimetry (ITC). It has been shown that in
vitro ULM/UHM recognition is sensitive to the solution ionic
strength. To compare directly the Kd values with the literature
data [21], the ITC measurements were performed at physiological
ionic strength (150 mM NaCl) (Table 1 and Figure S1). The
affinity decreases by one order of magnitude upon increasing the
NaCl concentration, likely as a consequence of an unfavorable
entropic effect and in agreement with the expected electrostatic
nature of the interaction [21,23]. Phosphorylation of S776
modulates the Atx1 ULM/U2AF65 UHM interaction by
decreasing the affinity approximately three fold.
U2AF65 Interacts with Atx1 In Vivo
While in vivo interaction of Atx1 with SPF45 has been fully
demonstrated [18], an interaction with U2AF65 was only
suggested by a two-hybrid-screen assay [26]. To test the
interaction in vivo, we initially performed confocal microscopy
co-localization experiments using RFP-tagged Atx1. Analysis of
HeLa cells co-expressing the proteins revealed that endogenous
U2AF65 and non-expanded Atx1 partially co-localize in the
nucleoplasm and in speckle-like structures (Figure 3A). PolyQ
expanded Atx1 is known to form large nuclear inclusions [10–14].
When we analyzed cells co-expressing endogenous U2AF65 and
Figure 2. Mapping the effect of Atx1 peptides on U2AF65. Weighted chemical shift perturbation of U2AF65 upon titration with
Atx1_S_ULM_PE (upper panel) and Atx1_pS_ULM_PE (lower panel). The U2AF65 sequence and secondary structure elements are indicated.
doi:10.1371/journal.pone.0008372.g002
Table 1. Summary of the Kd’s as obtained from ITC measurements carried out with the different peptides.
Peptide Sequence U2AF65_UHM SPF45_UHM 14-3-3f
Atx1_S_ULM 769 777 ATRKRRWSA 0.260.03 mM
a 5.660.3 mM n.d.
b n.d.
Atx1_pS_ULM 769 777 ATRKRRWpSA 0.660.08 mM
a 18.460.7 mM n.d. 1.060.1 mM
Atx1_S_ULM_PE 769 779 ATRKRRWSAPE 9.260.3 mM2 3 . 4 61.5 mM n.b.
c
Atx1_pS_ULM_PE 769 779 ATRKRRWpSAPE3 5 . 8 61.3 mM4 0 . 0 61.6 mM0 . 4 60.03 mM
Atx1_A_ULM_PE 769 779 ATRKRRWAAPE 8.960.4 mM2 2 . 5 60.6 mM n.b.
Atx1_D_ULM_PE 769 779 ATRKRRWDAPE 6.460.7 mM 0.960.07 mM n.b.
ULM and 14-3-3- binding motifs are underlined on the peptide sequences and marked in bold and italic, respectively.
a20 mM sodium phosphate buffer (pH 6.4), 30 mM NaCl, 5 mM DTT. Otherwise, 50 mM sodium phosphate buffer (pH 7.0), 150 mM NaCl, 5 mM DTT.
bn.d.: binding not determined.
cn.b.: binding not detectable.
doi:10.1371/journal.pone.0008372.t001
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inclusions formed by expanded Atx1 (Figure 3A).
To further confirm the interaction of Atx1 and U2AF65, we
then performed co-immunoprecipitation experiments. Lysates
from HeLa cells expressing flag-tagged non-expanded or expand-
ed Atx1 were subjected to immunoprecipitation using anti-flag
antibodies. Transferring the precipitated complexes onto nitrocel-
lulose membrane and probing with anti-U2AF65 antibody
revealed the presence of endogenous U2AF65 in the precipitates
(Figure 3B). To verify the interaction further, we immunopre-
cipitated the lysates with anti-U2AF65 antibodies and probed the
immune complexes with anti-flag antibodies (Figure 3B). The
interaction was also verified by co-immunoprecipitation experi-
ments using mouse cerebellum extracts. Immunoprecipitation of
the extracts with anti-Atx1 antibody followed by immunoblotting
with anti U2AF65 antibody, or immunoprecipitation with anti-
U2AF65 antibody and immunoblotting with anti-Atx1 antibody
both indicated that endogenous Atx1 and U2AF65 from the
extracts associate with each other (Figure 3C).
As some of the co-localization appeared to involve the speckle-
likestructuresformedbynon-expanded Atx1,wewanted toconfirm
whether these speckle-like structures are true nuclear speckles where
splicing factors are known to accumulate [33]. We observed that the
endogenous nuclear speckles formed by a nuclear speckle marker,
SC-35, did not co-localize with over-expressed Atx1 (Figure 3D).
Interestingly, while SC-35 and over-expressed U2AF65 did co-
localize in the nucleus, there were speckle-like formations of
U2AF65 that were devoid of SC-35 (Figure S2).
To address the question of whether interaction with Atx1
influences the cellular functions of U2AF65, we carried out
Figure 3. Interaction of Atx1 with U2AF65. A. Co-localization of Atx1 with endogenous U2AF65 in HeLa cells transfected with RFP-tagged Atx1
constructs and analysed by confocal microscopy. Non-expanded (30Q) or expanded Atx1 (82Q) (red) co-localized with endogenous U2AF65 (green),
as evidenced by the merged images. B. Interaction of Atx1 with endogenous U2AF65 in HeLa cells. HeLa cells were transfected with flag tagged non-
expanded Atx1 (lane 1), expanded Atx1 (lane 2) or empty pCMV constructs (lane 3). Lysates from these cells were immunoprecipitated with anti-flag
or anti-U2AF65 antibodies. Pelleted samples were analysed by western blot using anti-U2AF65 and anti-flag antibodies (IP). 5% of the lysates from
transfected cells were analysed by western blot using respective antibodies (Input). Molecular weight markers are shown on the left. C. Association of
Atx1 with U2AF65 in cerebellum extracts from mouse brain. The extracts were subjected to immunoprecipitation with anti-Atx1 antibodies, anti-
U2AF65 antibodies or control anti-flag antibodies. 2.5% of pelleted complexes from anti-U2AF65 IP (lane 1) and 25% from anti-flag IP (lane 2) and
anti-Atx1 IP (lane 3) were subjected to PAGE and Western blot analysis using anti- U2AF65 antibodies. 2.5% of pelleted complexes from anti-Atx1 IP
(lane 4) and 25% from anti-flag IP (lane 5) and anti-U2AF65 IP (lane 6) were subjected to PAGE and Western blot analysis using anti-Atx1 antibodies. D.
Atx1 does not localize with a nuclear speckle marker. HeLa cells were transfected with RFP-tagged non-expanded (30Q) or expanded (82Q) Atx1 (red).
Cells were fixed, permeabilized and stained with anti-SC-35 antibodies followed by FITC conjugated secondary antibodies (green). Merged images
indicate that neither forms of Atx1 co-localize to the speckles defined by SC-35.
doi:10.1371/journal.pone.0008372.g003
A Novel Motif in Ataxin 1
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8372preliminary studies assessing pre-mRNA binding by U2AF65. It
was shown recently that forced expression of Sam68, a U2AF65
binding protein, increases CD44 minigene pre-mRNA binding by
U2AF65 [34]. In our studies, we assessed CD44 pre-mRNA
occupancy by carrying out RNP immunoprecipitation of lysates
from cells expressing the two proteins followed by RT-PCR using
primers specific for the CD44 minigene. We were able to amplify
the CD44 signal from the immunoprecipitates of these cells.
However, we observed no significant difference when the cells co-
expressed Atx1 (Figure S3), suggesting absence of interference.
Atx1 Has a Positive Effect on U2AF65 Splicing
To test whether association of Atx1 with U2AF65 is splicing-
related, we carried out a splicing assay using the reporter pyPY
mini-gene, which was previously shown to give rise to a primary
transcript incorporating two alternative 39 sites associated with a
weak or strong polypyrimidine tract [35]. In agreement with the
previous study, transfection of 293T cells with the pyPY mini gene
construct and subsequent RT-PCR analysis revealed three bands:
a top band corresponding to the primary unspliced transcript, a
middle band resulting from the use of the proximal 39 weak (py)
splice site, and a bottom band from the strong distal 39 splice site
(PY) (Figure 4A, lane 1). As previously observed [35], over-
expression of U2AF65 enhances the splicing from the proximal
weak splice site (Figure 4A, lane 2).
We investigated whether Atx1 might have an effect on U2AF65
mediated splicing. To this end we transfected 293T cells with the
pyPY minigene and Atx1 in the presence and in the absence of
U2AF65. Total RNA was isolated from the cells 24 h post
transfection and quantitative RT-PCR analysis was carried out
using specific primers to amplify the two spliced isoforms
(Figure 4B). In each case, we first analyzed the ratio between
the py and PY isoforms, taking the cells singly transfected with the
pyPY minigene and empty vectors as reference (Figure 4C, bar
1). In agreement with the previous report [35], over-expression of
U2AF65 was found to enhance the usage of the proximal 39 weak
splice site, resulting in a significant increase in the pyPY ratio
(Figure 4C, bar 2). In cells transfected with the reporter
minigene and either non-expanded or expanded Atx1 (Figure 4C,
bars 3 and 4), the py/PY ratio obtained was more than the value
obtained when the reporter minigene was co-transfected with
empty vectors (Figure 4C bar 1). Co-transfection of U2AF65
Figure 4. Effect of Atx1 overexpression on alternative splicing of pyPY. A. Alternatively spliced transcripts from cells expressing the pyPY
minigene. 293T Cells were transfected with the pyPY reporter minigene plasmid. RNA was isolated 24 h post transfection and RT- PCR analysis was
carried out. The predicted alternatively spliced and unspliced primary transcripts are shown on the right by diagrams in which the exons and introns
are symbolised by boxes and lines, respectively. Molecular weight markers are indicated on the left. B. Schematic representation of the positions of
forward (For) and reverse (Rev) primers used in Quantitative RT-PCR analysis. C. Quantitative RT-PCR analysis of the expression levels of transcripts.
293T cells were transfected with pyPY reporter minigene plasmid together with empty pCMV vector (bar 1), GFP-U2AF65 (bar 2), flag-30Q-Atx1 (bar
3), flag-82Q-Atx1 (bar 4), GFP-U2AF65 and flag-30Q-Atx1 (bar 5) or GFP-U2AF65 and flag-Atx1 82Q plasmids (bar 6). Total RNA was isolated from the
cells 24 h post transfection and quantitative RT-PCR analysis using the primer sets shown in B was carried out. The histogram shows the ratios
between the isoform levels (py/PY). Values are mean 6 standard deviation from four experiments. 11 indicates P,0.01 GFP-U2AF65 and flag-30Q-
Atx1 vs GFP-U2AF65 alone; * indicates P,0.05 flag-30Q-Atx1 vs empty pCMV vector. Statistical significance was evaluated with One-way analysis of
variance followed by Turkey’s Multiple Comparison Test. D. Expression of proteins in 293T cells transfected with reporter minigene, U2AF65 and Atx1
constructs. Lanes 1 to 6 correspond to bars 1 to 6 shown in C. Cell extracts were prepared 24 h after transfection and the proteins were analysed by
Western blotting with indicated antibodies. Molecular weight markers are indicated on the left.
doi:10.1371/journal.pone.0008372.g004
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proximal site (Figure 4C, bars 5 and 6). Further pairwise
comparison of subgroups (i.e, control versus cells over-expressing
Atx1 constructs, and U2AF65 over-expressing cells versus cells
over-expressing both U2AF65 and Atx1) revealed that only non-
expanded Atx1 has a significant effect on pyPY splicing
(Figure 4C bar 3 and 5).
Expression of U2AF65 and Atx1 constructs in transfected 293T
cells with reporter minigene was compared by Western blot
analysis (Figure 4D). The results indicated similar expression
levels.
Taken together these results point towards a positive effect of
Atx1 over-expression on U2AF65-mediated splicing.
14-3-3 Prevents U2AF65 UHM from Binding to S776
Phosphorylated Atx1
Since S776 phosphorylated Atx1 binds also the 14-3-3 protein
[17], we compared the affinity of this interaction. We used a
peptide C-terminally extended as compared to the one previously
designed to probe interaction with U2AF65 UHM so to include
P778 and encompass the complete 14-3-3 ‘mode II’ recognition
motif [31] (Atx1_pS_ULM_PE, residues 769–779). We compared
the affinities of this peptide with the non-phosphorylated version
(Atx1_S_ULM_PE) and with the shorter Atx1_pS_ULM peptide.
Among the nine highly homologous 14-3-3 isoforms, expanded
Atx1 has been found to interact in vivo with e, f, g, c, and b
isoforms [17]. We chose to work with isoform f (14-3-3f) since it is
present in high concentrations in the neuronal nucleus of all the
major affected areas in SCA1 brains [36].
The Kd between 14-3-3f and Atx1_pS_ULM_PE is two orders
of magnitude smaller than the value measured for U2AF65 UHM
(Table 1) indicating that 14-3-3f binding of S776 phosphorylated
Atx1 could prevent it from binding to UHMs domains. We probed
competition of the two proteins for the Atx1_pS_ULM_PE
peptide by NMR titrating unlabelled 14-3-3f to
15N labeled
U2AF65 UHM saturated with unlabelled Atx1_pS_ULM_PE.
The HSQC spectrum of free U2AF65 UHM is restored by
addition of a 1:1 ratio of 14-3-3f/Atx1_pS_ULM_PE, indicating
that U2AF65 has been displaced by 14-3-3f (Figure 5).
Phosphorylation of S776 was confirmed to be an absolute
requirement for binding to 14-3-3, while absence of P778 in
Atx1_pS_ULM, a residue highly conserved in Atx1 and in both
14-3-3 ‘mode I’ and ‘mode II’ motifs, only slightly decreased the
affinity, still leaving the Kd for 14-3-3f one order of magnitude
lower than for U2AF65. We also tested by ITC the binding of a
S776A-mutated peptide (Atx1_A_ULM_PE) to U2AF65 UHM,
since it has been shown that Q82-expanded Atx1 carrying a
S776A mutation still localizes in the nucleus in transfected cells
and in Purkinje cells of transgenic mice but fails to form nuclear
inclusions [16]. We confirmed that S776A does not affect
substantially the ability of Atx1 to recognize UHM domains and
that S776A binds U2AF65 UHM with affinities comparable to the
wild-type.
Atx1 Also Recognizes the Regulatory Splicing Factor
SPF45 through a ULM-UHM Interaction
We then reasoned that UHM/ULM interactions might be
important also to recognize SPF45, another Atx1 interacting
protein which also contains a UHM. To check this hypothesis we
extended our ITC studies to this protein (Table 1). We observed
that Atx1_S_ULM_PE binds SPF45 UHM with lower affinity
than U2AF65 UHM but, similarly to what observed with
U2AF65, S776 phosphorylation weakens the interaction although
to a lower extent. Our in vitro findings using isolated
Atx1_S_ULM_PE and SPF45 UHM indicate weak negative
rather that positive regulation of the interaction by S776
phosphorylation, in contrast with what observed by co-immuno-
precipitation assays from lysate of co-transfected HEK293T cells
[18]. These experiments were however carried out using an
S776D mutant which should mimic phosphorylated Atx1. To
investigate the reasons of these apparently contradictory data, we
measured the affinity of both U2AF65 and SPF45 UHMs and 14-
3-3f for a S776D peptide (Atx1_D_ULM_PE). No binding to 14-
3-3f was detected, not even when titration was performed at a
0.22 mM 14-3-3f concentration, indicating that aspartate does not
properly mimic S776-phosphorylation. Conversely, a two-order of
magnitude increase of affinity to SPF45 UHM was observed, while
affinity to U2AF65 UHM was not significantly affected. Taken
together, these findings confirm that S776 phosphorylation plays a
limited and direct role in down-regulating Atx1 binding to UHMs
and fully explain the differences observed in vivo with the S776D
mutant [18].
Modeling of the Complex Allows Rationalization of the
Results
To rationalize our results we analyzed the structures of the other
UHM/ULM complexes of U2AF65/SF1 (PDB code 1opi, [23])
and SPF45/SF3b155 (2peh, [21]). In the U2AF65 UHM/SF1
ULM of 1opi, position W+1 of the SF1 ULM, which corresponds
to S776, is occupied by an asparagine that is fully exposed to the
solvent (46 A ˚ 2) and does not form contacts with U2AF65. In the
SF3b155 ULM5 of 2peh, the same position is occupied by an
aspartate. This negatively charged residue forms a hydrogen bond
with the side chain of a spatially close positively charged UHM
residue (i.e. R375 of SPF45) and drastically changes the ULM
conformation.
Using this information, we build homology models of the
U2AF65 UHM/Atx1 ULM and SPF45 UHM/Atx1 ULM
complexes using 1opi and 2peh as templates (Figure 6). When
position 776 of Atx1 ULM is occupied by a neutral serine or
alanine Atx1_S_ULM_PE and Atx1_A_ULM_PE are likely to
adopt a conformation similar to that observed in 1opi, with the
Figure 5. Testing competition of Atx1_pS_ULM_PE binding to
14-3-3f and U2AF65_UHM.
15N labeled U2AF65_UHM saturated
with unlabelled Atx1_pS_ULM_PE was titrated with unlabelled 14-3-3f.
The HSQC spectra of U2AF65 UHM in its free form (red), saturated with
a 2 fold molar excess of Atx1_pS_ULM_PE (green) and saturated with a
1:1 14-3-3f/Atx1_pS_ULM_PE mixture in a 2 fold molar excess to
U2AF65 UHM (blue) are compared.
doi:10.1371/journal.pone.0008372.g005
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t h e s ec o m p l e x e sa r ec o m p a r a b l e( Table 1). When S776 is
replaced by an aspartate, this residue will likely behave as in
SF1 ULM and form a hydrogen bond with R375 of SPF45 as
in 2peh. This explains why we observe a tighter interaction for
the SPF45/Atx1_D_ULM_PE.complex. A similar stabilization
is not possible when Atx1_ with U2AF65 UHM likely because
the mutated D776 is surrounded not only by R452 of U2AF65
(which corresponds to R375 of SPF45) but also by the positive
side chains of K453. The three positively charged residues
could compete, thus not allowing preferential orientation of the
aspartate side-chain for optimal coordination with R452. An
aspartate in position W+1 seems to be conserved in all the
ULM ligands known to interact with high affinity to UHMs in
which the X of the Arg-X-Phe motif is an aromatic (i.e. Y or
W) instead of a positively charged residue. These include
SPF45 UHM/SF3b155 ULM5 [21], U2AF35 UHM/U2AF65
ULM [21,22] and PUF60 UHM/SF3b155 ULM1 and ULM3
[37]. Finally, it is clear from both models that a phosphate
group at S776 is too bulky to form a hydrogen bond with the
protein, thus explaining the slight destabilising effect of
phosphorylation.
Figure 6. Structural models of U2AF65 and SPF45 in complex with the Atx1 native and S776D mutant ULMs. The structures of 1opi and
2peh were used as homology modeling templates for the complexes of U2AF65 (left) and SPF45 (right), respectively. In the 1opi complex (left), the
SF1 ULM peptide (PSKKRRKRSRWNQD) contains an Asn in correspondence to Atx1_ULM S776. The top panel shows a blow-up of the peptide and of
R452 and K453 in the same orientation as shown below. The residue does not pack against the protein and is exposed. In the 2peh complex (right),
the aspartate in position W+1 of the SF3b155 ULM5 peptide (KRKSRWDETP) hydrogen bond with the spatially close R375 of SPF45. These coordinates
are therefore more appropriate to model the structure of the S776D mutant. The top panel shows a blow-up of the hydrogen bond between S776D
with the side chain of R375, as rotated by 290 degrees around the y axis.
doi:10.1371/journal.pone.0008372.g006
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It is common when studying proteins associated with diseases to
consider them mainly under the aspect of how they are linked to
pathology. This is particularly the case for polyQ proteins: much
has been said about their relationship to aggregation and cellular
toxicity but still little is known about their cellular functions when
they are in their non-pathologic state. In this study, we have
followed a different approach. We focused on the functional role of
non-pathologic Atx1 and set out to identify sequence motifs which
could provide direct information about the mechanisms involved
in recognition.
Although a role in transcriptional regulation, often mediated by
interaction of the AXH domain with several transcriptional co-
regulators [10–14,38,39] has also been suggested, independent
evidence indicates that Atx1 is an RNA binding protein with a role
in processing and/or exporting specific mRNAs to the cytoplasm:
Atx1 recognizes RNA homo-polymers [9,40]; it is linked directly
through its interactome to other RNA binding proteins, some of
which are splicing factors [18,26]; Atx1 was shown to recruit the
mRNA export factor TAP/NXF1 [41].
We have shown in this study that Atx1 interacts with U2AF65,
thus adding a new member to the Atx1 interactome. Atx1 does not
co-localize with nuclear speckles, the subnuclear structures in
which splicing factors accumulate when not actively forming
spliceosomes (reviewed in [42]). A splicing-independent association
in extraspliceosomal complexes has recently been described for the
splicing factors SF1 and U2AF [43].
Our splicing assays suggest an enhancing effect of Atx1 over-
expression on U2AF65-mediated splicing. While the exact
implications for the function of Atx1 in the context of splicing
remain to be investigated in detail, it is worth noting that only non-
expanded Atx1 seems to have a significant effect on U2AF65-
mediated splicing suggesting that polyQ expansion could interfere
with molecular recognition. Addionally, recruitment or trapping of
U2AF65 in the single large nuclear aggregates of SCA1 affected
neurons could have a detrimental effect on splicing.
Even more relevant for understanding the functions of native
Atx1 is the identification of the motif that mediates the interaction:
the presence of a ULM in the C-terminus of Atx1 strongly
supports an involvement of the protein in pre-mRNA splicing and
a direct involvement in the complex and highly dynamic
macromolecular machinery represented by the spliceosome
[25,44–46]. This is in line with the reported presence of non-
expanded Atx1 in a large protein complex associated in an RNA
dependent fashion with the regulatory splicing factor SPF45 (this
complex is most likely the early stage complex known as pre-
spliceosome although no attempt to identify it was made) [18].
Since many of the splicing factors contain ULM, UHM or both
motifs, our results point directly to a participation of Atx1 to the
network of multiple and competing interactions linking the splicing
factors.
Further complexity to the overall picture is added by the
presence of overlapping functional sites in Atx1. Two motifs
overlap with ULM, the NLS and the 14-3-3 phospho-S776 ligand
motif, known to be essential requirements for the functions of the
protein and for development of disease. This prompted us to check
the effect of phosphorylation on interaction and to compare our
results with a previous study which describes binding of Atx1 with
SPF45 by two-hybrid screen and co-immunoprecipitation from
mammalian cells [18]. Because of the techniques used, the authors
made the a priori reasonable assumption that the effect of
phosphorylation could be mimicked or abolished by mutation of
S776 to an aspartate and to an alanine respectively. They
demonstrated that both wild-type and S776D Atx1 interact with
SPF45 and that the interaction is strengthened for S776D but
abolished when using a S776A mutant. These data are in some
agreement with our in vitro binding assays but as compared to the
non-phosphorylated Atx1 ULM, the phosphorylated peptide binds
with lower affinity. This indicates that aspartate does not have the
correct properties to mimic a phosphate group, likely because it is
smaller, unbranched and with a lower charge density, as further
confirmed by observing that the S776D mutant peptide is not
recognised by 14-3-3f.
S776 is therefore the molecular switch between alternative
interactions: when non-phosphorylated, non-expanded Atx1 will
be involved through its ULM in a vast network of interactions with
splicing factors and contribute to the spliceosome. Phosphorylated
Atx1 will bind instead 14-3-3. Phosphorylated Atx1 also recognises
other cellular partners as shown by the evidence that the
interactions with the transcriptional repressor Capicua (CIC)
which targets the AXH domain of Atx1 [12] and other proteins
involved in transcriptional regulation, such as the MEF2-HDAC4
complex [38], are weakened in the S776A mutant.
How do these findings tell us something about disease and how
do interactions and signal overlap affect SCA1? It has been
suggested that this pathology could be the result of the balance
between a gain-of-function due to enhancement of interaction with
SPF45 and a partial loss-of-function due to weakening of
interaction with CIC. A different, non-mutually exclusive
possibility is that phosphorylation causes Atx1 to interact with a
substantially different network of nuclear proteins than non-
phosphorylated Atx1 [6]. Our findings that Atx1 binding to
UHMs is modulated in a posphorylation-dependent manner due
to the intervention of 14-3-3 open a scenario that would merge the
two hypotheses.
We have demonstrated that the S776A mutant peptide is able to
recognize U2AF65 with affinity comparable to that of the native
ligand sequence. This indicates that non-phosphorylated expand-
ed Atx1, which does not manifest a SCA1 phenotype as we know
from the S776A mutant [16], still recognizes UHM-containing
nuclear factors despite being unable to bind 14-3-3. We suggest
(Figure 7) that participation of Atx1 in these interactions plays a
protective role against self-association of the protein induced by
polyQ expansion: the spliceosome is a large and dynamic
machinery composed of five major small nuclear ribonucleopro-
tein particles including U2 of which U2AF is an auxiliary factor,
and more than three hundred non-snRNP protein splicing factors
[25,44–46]. Engagement in such an extended protein complex
could easily ‘dilute out’ expanded Atx1 and prevent or reduce its
self-association to an extent that allows efficient clearance by the
machinery of the proteasome pathway. Conversely, when Atx1 is
S776-phosphorylated and recruited by 14-3-3, the interaction with
the spliceosome complex is hampered. As a consequence,
expanded Atx1 becomes available both to self association through
regions such as the polyQ stretches and/or the AXH domain [10],
and to recognition of other partners. In support of this hypothesis
is also the presence of the 14-3-3f isoform in protein aggregate
deposits observed in different neurological diseases, such as
Parkinson and Alzheimer diseases, Huntington and SCA1 itself
[47,48]. The effect is particularly evident in SCA1 where the 14-3-
3f isoform changes localization from the cytoplasm to the nucleus
of affected Purkinje cells [36].
An important point that becomes clear from our studies is the
importance of investigating the non pathologic molecular
interactions as a strategy to identify mechanisms that prevent
aggregation. Also, it is clear that it is far too simplistic to approach
SCA1 or other polyQ diseases in terms of a gain or loss-of-
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function is described in terms of enhanced or reduced interactions
and strongly depend on which of the several interactions we may
refer to. As remarked in a recent review [49] and as indicated by
our results, polyQ proteins take part in a complex and vast
network of interactions, to which polyQ aggregation adds another
competing pathway.
For complex regulatory systems, the difficult balance of multiple
equilibria can only be appropriately described by gaining an
overall picture which places each interaction into the bigger frame
of all what is known about the individual components [50]. It will
be interesting to investigate further the role of different regions of
Atx1 in modulating interactions since SPF45 and CIC, although
binding to different sites, i.e. ULM and AXH, compete with each
other [12,18].
Methods
Protein Preparation
Unlabelled recombinant U2AF65 UHM (residues 369–475) and
SPF45 UHM (residues 301–401) were over-expressed in the E. coli
host strain BL21 (DE3)pLysS in Luria Broth medium using a
kanamycin-resistant pETM30 vector with tobacco etch virus
(TEV)-cleavable N-terminal His6-GST tags. Isotopically
15N- and
13C/
15N labelled samples were expressed in minimal (M9)
medium containing
15N-ammonium sulphate and
13C-glucose as
the sole sources of nitrogen and carbon, respectively. The cells
were grown at 37uC until an optical density (OD) at 600 nm of 0.6
was reached, then induced with IPTG (0.25 mM) and harvested
after three hours. A standard purification protocol was performed
using a Ni-NTA agarose column (Qiagen) except that no imidazol
was added before elution. The proteins were further purified by
FPLC size exclusion chromatography using a prepacked HiLoad
16/60 Superdex
TM 75 prep grade column (Pharmacia). Synthetic
Atx1 peptides were purchased from Pepceuticals Limited (Notting-
ham-UK) and used after having been freed from residual
trifluoroacetic acid by repeated steps of dissolution in sterile
double-distilled water and lyophilization. Protein and peptide
concentrations were checked by measuring UV absorbance at
280 nm.
NMR Experiments
NMR experiments were performed at 295 K on Bruker Avance
600 and Varian Inova 800 spectrometers, both equipped with
cryoprobes. Samples of
15N labelled U2AF65 UHM and SPF45
UHM used for the NMR experiments were concentrated to
0.2 mM and dialysed either against 20 mM sodium phosphate
buffer (pH 6.4), 30 mM NaCl, 5 mM DTT, or 50 mM sodium
phosphate buffer (pH 7.0), 150 mM NaCl, 5 mM DTT (for the
U2AF65 UHM/14-3-3f competition experiment). Titrations were
performed with stepwise additions of concentrated stock solutions
of Atx1 ULM peptides up to a 2–3 fold molar excess.
Comparative Modelling
The U2AF65 and SPF45 UHM/Atx1 ULM complexes were
modeled by homology using the coordinates of the U2AF65
UHM/SF1 ULM (PDB code 1opi, [23]) and SPF45/SF3b155
ULM5 (2peh, [21]). The Biopolymer module of Insight2 (Accelrys,
San Diego) was used to replace the peptide side chains. The
obtained models were submitted to 100 cycles of energy
minimization to regularize the geometry.
ITC Measurements
Binding affinities of U2AF65 UHM, SPF45 UHM and 14-3-3f
with Atx1 ULM ligands were measured at 295 K by a MicroCal
Omega VP-ITC (MicroCal Inc., Northampton, USA). All the
proteins were dialyzed against 50 mM sodium phosphate buffer
(pH 7.0), 150 mM NaCl and 5 mM DTT. Solutions of 0.025–
0.4 mM UHM proteins in the cell were titrated by injections of a
total of 295 ml of 0.25–3.9 mM peptide in the syringe in 21
aliquots. The concentrations of the 14-3-3f and ATX1 ULM
ligands were adjusted to 0.012–0.037 mM and 0.1–0.4 mM
respectively. Data were processed with the software MicroCal
Origin version 5.0 provided by the manufacturer. All dissociation
constants were averages of three measurements.
Confocal Microscopy
For co-localisation experiments, expanded and non-expanded
Atx1 were cloned into pBudCE4.1 vectors expressing monomeric
Red Fluorescence Protein (RFP). HeLA cells were transfected with
expanded or non-expanded Atx1-RFP constructs. Immunofluo-
rescence was carried out as described previously [51]. Briefly, the
cells were fixed 24–48 h after transfection using 4.0% parafor-
maldehyde, permeabilised with 0.2% triton X-100/PBS and
probed with anti-U2AF65 monoclonal antibodies (Sigma) followed
by FITC conjugated secondary antibodies. For Atx1 localization
studies with a nuclear speckle marker, cells were transfected with
Atx1-RFP constructs and stained with anti SC-35 monoclonal
antibodies (Abcam Plc) followed by FITC conjugated secondary
antibodies. After washing with PBS, slides were mounted using
Citifluor (Agar Scientific) and analysed by confocal microscopy.
Cells were visualised under a Leica laser scanning confocal
Figure 7. Schematic model of the cellular interactions formed
by Atx1 and the role that phosphorylation plays in pathology.
S776 phosphorylation would be at the crossing point of two different
pathways. When Atx1 (blue oval) is not phosphorylated, it interacts with
the spliceosome (light blue shape) and is protected from aggregation.
Phosphorylated Atx1 has higher affinity to 14-3-3 proteins but is not
protected against self-association. In vitro, the Ala mutant mimics
correctly the properties of non-phosphorylated Atx1, whereas the Asp
mutant, which has properties very different from the phosphorylated
sequence, is not recognized by 14-3-3.
doi:10.1371/journal.pone.0008372.g007
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and an argon-krypton laser. Images were acquired as single
0.2 mm trans-cellular optical sections and averaged over 20 scans
per frame. Images were acquired sequentially and appropriate
emission filter settings and controls were included to minimize
bleed-through effects.
Co-Immunoprecipitation
HeLa cells were plated at equal density and transfected with
either flag-tagged Atx1 constructs or with empty pCMV flag
vectors. Cells were trypsinised, pelleted and washed with PBS. 5%
of the cell pellet was solubilized with SDS sample buffer and
subjected to western blot analysis by respective antibodies to check
expression levels. The rest of the cells were lysed in TS buffer
(20 mM Tris-HCl pH 7.5, 75 mM NaCl) containing 1.0% NP40
and supplemented with protease and RNAse inhibitors. The
cleared lysate was diluted 6 times with TS buffer without detergent
and incubated with either Atx1 (11NQ, obtained from NeuroMab
Facility, University of California, Davis) or U2AF65 (Sigma)
monoclonal antibodies and protein A/G agarose at 4uC overnight.
Pellets were washed three times with TS buffer. After SDS-PAGE,
Atx1 and U2AF65 were detected by immunoblotting with anti-flag
and anti-U2AF65 antibodies and peroxidase conjugated Light
Chain specific anti-mouse IgG secondary antibodies (Jackson
ImmunoResearch). Cerebellum extracts were prepared by ho-
mogenizing tissue in TS buffer containing 1.0% NP40 and
protease/RNAse inhibitors) using a Polytron PT 3000 homoge-
nizer. Cleared lysates were diluted 6 times with TS buffer without
detergent. 500 ml of lysates (1.0 mg protein) were used to perform
immunoprecipitation using the anti-Atx1 monoclonal antibody
11NQ. Similar amounts of lysates were used for immunoprecip-
itation using anti-U2AF65 monoclonal antibodies or a control
monoclonal antibody (anti-flag antibody, Sigma). Pellets were
washed with TS buffer, resuspended and boiled in sample buffer.
Immunoprecipitated samples were analysed by PAGE and
Western blot using anti-Atx1 or anti-U2AF65 antibodies.
Splicing Assay
HeLa cells were transfected with pyPY minigene encoding
plasmids. 24 h post transfection, total RNA was prepared from the
cells using RNAspin mini RNA purification system (GE Health-
Care). For RT PCR analysis, first strand synthesis was carried out
using Superscript III qRT-PCR mix (Invitrogen) and the PCR
products were separated on agarose gels and detected by ethidium
bromide staining. The following primers were used for the PCR:
59 TGAGGGGAGGTGAATGAGGAG 39and 59 TCCACTG-
GAAAGACCGCGAAG 39.
To analyse the effect of Atx1 on splicing, 293T cells were plated
on 24 well plates and co-transfected with pyPY reporter minigene
and GFP-U2AF65 plasmids (both kindly supplied by Dr Juan
Valca ´rcel), in the presence and absence of Atx1 expression vectors.
Control cells were transfected with pyPY reporter and appropriate
empty vectors. Total RNA was isolated after 24 h as described
above. First strand synthesis was carried out using the Quantitect
reverse transcription kit (Qiagen). Real-time quantitative PCRs
were performed on a Rotor Gene 6000 real-time rotary analyzer
(Corbett Research) using SensiMix Plus SYBR kit (Quantace).
Annealing and extensions were carried out at 60uC and 72uC,
respectively. Absolute copy numbers of the transcripts derived
from standard curves were used to generate py/PY ratios.
Sequence of the forward primer and the reverse primers used
were as follows: forward primer, 59 AGGCTTTGAGAAC-
CTGTGGA 39. Distal reverse primer, 59 CCTCAACCGCGA-
GCTTGA 39. Proximal reverse primer, 59 GAGAGTCATTT-
CACCTTGA 39. The PCR products were confirmed by
sequencing. Statistical analyses were performed with Prism
software (GraphPad software). All values are expressed as mean
6 standard deviations from four independent experiments.
Statistical analysis was assessed by One-way ANOVA followed
by Turkeys Multiple Comparison Test. Probabilities (P) ,0.05
were considered significant.
Supporting Information
Figure S1 ITC profiles for the binding of the Atx1 peptides. In
each panel, the raw data relative to sequential injections are shown
in the upper plot; the lower plot represents the resulting integrated
enthalpy data fit to a single-site binding model (solid line). The
curves represent the titration of Atx1_S_ULM_PE, Atx1_p-
S_ULM_PE and Atx1_D_ULM_PE (from left to right) with
U2AF65 (upper panel) and 14-3-3f (lower panel).
Found at: doi:10.1371/journal.pone.0008372.s001 (1.92 MB TIF)
Figure S2 Some speckle-like formations of U2AF65 are devoid
of SC-35. HeLa cells were transfected with GFP-U2AF65. Fixed,
permeabilized cells were probed with antibodies against nuclear
speckle marker SC-35 followed by TRITC conjugated secondary
antibodies. Confocal Microscopy: HeLa cells growing in chamber
slides were transfected with GFP-U2AF65 constructs. Cells were
fixed and permeabilized and incubated with anti SC-35
monoclonal antibody (Abcam Plc) followed by secondary antibod-
ies conjugated to TRITC. After washing with PBS, slides were
mounted using Citifluor (Agar Scientific) and analysed by confocal
microscopy. Cells were visualised under a Leica laser scanning
confocal microscope (TCS-SP1) equipped with a DM-RXE
microscope and an argon-krypton laser. Images were acquired
as single 0.2 mm transcellular optical sections and averaged over
20 scans/frame. Images were acquired sequentially and appro-
priate emission filter settings and controls were included to
minimize bleed-through effects. Images were merged using the
ImageJ program (NIH, Bethesda). Merged images show the details
observed in a single 0.2 mm optical section.
Found at: doi:10.1371/journal.pone.0008372.s002 (0.54 MB TIF)
Figure S3 Assessment of CD44 pre-mRNA occupancy. Cells
were transfected with GFP-U2AF65, empty pCMV-flag vector,
CD44 minigene construct and CAT expression vector (lane1);
GFP-U2AF65, flag-expanded Atx1, CD44 minigene construct and
CAT expression vector (lane 2) or GFP-U2AF65, flag-unexpanded
Atx1, CD44 minigene construct and CAT expression vectors (lane
3). RNP immunoprecipitations were carried out and RT PCR was
performed using primers specific for CD44 (top panel). 5% of the
cells used for analysis were subjected to western blotting using anti
CAT antibodies (bottom panel). RNP Immunoprecipitation:
Experiments were carried out as previously described [1]. In
short, cells were transfected with GFP-U2AF65 and CD44
minigene constructs (kindly supplied by Dr. Harald Ko ¨nig,
Karlsruhe) and a CAT expression vector used as an internal
transfection control. Atx1 expression vectors were added in the
transfection mix to test the effect on pre mRNA occupancy. In
vivo crosslinking using 0.1% formaldehyde was carried out as
described [2]. 5% of the cross-linked cells were pelleted,
solubilized in SDS sample buffer and subjected to western blotting
with an anti CAT antibody (Sigma). The rest of the cross-linked
complexes were solubilized by sonification. Immunoprecipitation
was performed by incubating the lysates with polyclonal rabbit
anti-GFP antibody (Abcam) at RT for 90 min. Prior to
immunoprecipitation, protein A/G was incubated with 20 units
of RNasin (Promega) for 10 min. Immunoprecipitates were
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de-cross-linked in 100 ml 50 mM Tris-HCl pH 7.0, 1% SDS,
5 mM EDTA, 10 mM DTT at 70uC for 45 min and RNA was
extracted using Pure Link RNA purification system (Invitrogen)
followed by DNase digestion. Half of the RNA was reverse
transcribed by random priming. The following primers were used
as forward and reverse primers, TCATTATGACAGTTGCCAC-
CAG and TACTTGTGCTTGTAGCATGTGG, for detecting
the pre-mRNA fragment from the pETv5 minigene (607 bp in
length). Thirty-five PCR cycles (95uC for 1 min; 55uC for 1 min;
and 72uC for 1.5 min) were performed for amplification of
fragments from the transfected minigene. References 1. Tisserant
A, Konig H (2008) Signal-regulated Pre-mRNA occupancy by the
general splicing factor U2AF. PLoS ONE 3: e1418. 2. Niranja-
nakumari S, Lasda E, Brazas R, Garcia-Blanco MA (2002)
Reversible crosslinking combined with immunoprecipitation to
study RNA-protein interactions in vivo. Methods (San Diego,
Calif) 26: 182–190.
Found at: doi:10.1371/journal.pone.0008372.s003 (0.18 MB TIF)
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